Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Rating of “Hold” by Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been given an average rating of “Hold” by the eleven research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $20.2857.

Several brokerages have weighed in on JSPR. Evercore ISI dropped their target price on Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a research report on Monday, September 22nd. BTIG Research reduced their price target on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating for the company in a report on Monday, September 22nd. JMP Securities dropped their price objective on Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a report on Monday, September 22nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Wednesday, October 8th.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Velan Capital Investment Management LP increased its position in Jasper Therapeutics by 86.1% during the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after buying an additional 1,234,567 shares during the last quarter. Acorn Capital Advisors LLC acquired a new stake in shares of Jasper Therapeutics in the third quarter worth about $3,291,000. Kingdon Capital Management L.L.C. boosted its stake in shares of Jasper Therapeutics by 93.5% during the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,324,845 shares of the company’s stock worth $3,153,000 after acquiring an additional 640,138 shares in the last quarter. Woodline Partners LP acquired a new position in shares of Jasper Therapeutics during the 3rd quarter valued at about $2,475,000. Finally, Vanguard Group Inc. increased its holdings in shares of Jasper Therapeutics by 65.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,032,842 shares of the company’s stock valued at $2,458,000 after acquiring an additional 408,245 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Stock Down 5.2%

Shares of NASDAQ:JSPR opened at $1.81 on Wednesday. The firm has a fifty day moving average of $1.94 and a two-hundred day moving average of $2.91. The firm has a market capitalization of $50.64 million, a P/E ratio of -0.31 and a beta of 3.06. Jasper Therapeutics has a 12-month low of $1.39 and a 12-month high of $22.99.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.12). Equities research analysts expect that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.